Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors

E. P. Acosta, T. N. Kakuda, R. C. Brundage, P. L. Anderson, C. V. Fletcher

Research output: Contribution to journalArticle

108 Citations (Scopus)

Abstract

Many factors are involved in the success or failure of antiretroviral therapy. Recent data suggest that there are significant differences in drug absorption and disposition for the protease inhibitor class of antiretroviral drugs, and relationships between plasma concentrations and their antiviral effect have been described. Consequently, the issue of whether therapeutic drug monitoring should be employed for patients receiving treatment with these drugs has arisen. Several criteria must be met before a drug is considered a candidate for therapeutic drug monitoring. These criteria include pharmacological, clinical, and analytic components. Although not all the necessary criteria have yet been met, some of these components have been defined, and additional data are being generated. However, prospectively designed clinical trials must be completed to determine if monitoring protease inhibitor plasma concentrations provides additional clinical benefit to the patient.

Original languageEnglish (US)
Pages (from-to)S151-S159
JournalClinical Infectious Diseases
Volume30
Issue numberSUPPL. 2
DOIs
StatePublished - Dec 1 2000

Fingerprint

Protease Inhibitors
HIV-1
Drug Monitoring
Pharmaceutical Preparations
Antiviral Agents
Clinical Trials
Pharmacology
Therapeutics

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors. / Acosta, E. P.; Kakuda, T. N.; Brundage, R. C.; Anderson, P. L.; Fletcher, C. V.

In: Clinical Infectious Diseases, Vol. 30, No. SUPPL. 2, 01.12.2000, p. S151-S159.

Research output: Contribution to journalArticle

Acosta, EP, Kakuda, TN, Brundage, RC, Anderson, PL & Fletcher, CV 2000, 'Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors', Clinical Infectious Diseases, vol. 30, no. SUPPL. 2, pp. S151-S159. https://doi.org/10.1086/313852
Acosta, E. P. ; Kakuda, T. N. ; Brundage, R. C. ; Anderson, P. L. ; Fletcher, C. V. / Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors. In: Clinical Infectious Diseases. 2000 ; Vol. 30, No. SUPPL. 2. pp. S151-S159.
@article{90e8967db2f948aea46903c189d7cfc4,
title = "Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors",
abstract = "Many factors are involved in the success or failure of antiretroviral therapy. Recent data suggest that there are significant differences in drug absorption and disposition for the protease inhibitor class of antiretroviral drugs, and relationships between plasma concentrations and their antiviral effect have been described. Consequently, the issue of whether therapeutic drug monitoring should be employed for patients receiving treatment with these drugs has arisen. Several criteria must be met before a drug is considered a candidate for therapeutic drug monitoring. These criteria include pharmacological, clinical, and analytic components. Although not all the necessary criteria have yet been met, some of these components have been defined, and additional data are being generated. However, prospectively designed clinical trials must be completed to determine if monitoring protease inhibitor plasma concentrations provides additional clinical benefit to the patient.",
author = "Acosta, {E. P.} and Kakuda, {T. N.} and Brundage, {R. C.} and Anderson, {P. L.} and Fletcher, {C. V.}",
year = "2000",
month = "12",
day = "1",
doi = "10.1086/313852",
language = "English (US)",
volume = "30",
pages = "S151--S159",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors

AU - Acosta, E. P.

AU - Kakuda, T. N.

AU - Brundage, R. C.

AU - Anderson, P. L.

AU - Fletcher, C. V.

PY - 2000/12/1

Y1 - 2000/12/1

N2 - Many factors are involved in the success or failure of antiretroviral therapy. Recent data suggest that there are significant differences in drug absorption and disposition for the protease inhibitor class of antiretroviral drugs, and relationships between plasma concentrations and their antiviral effect have been described. Consequently, the issue of whether therapeutic drug monitoring should be employed for patients receiving treatment with these drugs has arisen. Several criteria must be met before a drug is considered a candidate for therapeutic drug monitoring. These criteria include pharmacological, clinical, and analytic components. Although not all the necessary criteria have yet been met, some of these components have been defined, and additional data are being generated. However, prospectively designed clinical trials must be completed to determine if monitoring protease inhibitor plasma concentrations provides additional clinical benefit to the patient.

AB - Many factors are involved in the success or failure of antiretroviral therapy. Recent data suggest that there are significant differences in drug absorption and disposition for the protease inhibitor class of antiretroviral drugs, and relationships between plasma concentrations and their antiviral effect have been described. Consequently, the issue of whether therapeutic drug monitoring should be employed for patients receiving treatment with these drugs has arisen. Several criteria must be met before a drug is considered a candidate for therapeutic drug monitoring. These criteria include pharmacological, clinical, and analytic components. Although not all the necessary criteria have yet been met, some of these components have been defined, and additional data are being generated. However, prospectively designed clinical trials must be completed to determine if monitoring protease inhibitor plasma concentrations provides additional clinical benefit to the patient.

UR - http://www.scopus.com/inward/record.url?scp=0034458321&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034458321&partnerID=8YFLogxK

U2 - 10.1086/313852

DO - 10.1086/313852

M3 - Article

C2 - 10860900

AN - SCOPUS:0034458321

VL - 30

SP - S151-S159

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - SUPPL. 2

ER -